We appreciate the comments from Dr. Zografos and Dr. Roukos regarding our research on the use of contralateral prophylactic mastectomy (CPM). We previously reported that the CPM rate in the United States increased by more than 150% from 1998 to 2003 among patients with unilateral invasive breast cancer.
Although absolute indications for CPM are not established, the Society of Surgical Oncology has published criteria that physicians should consider for mastectomy of the contralateral, intact breast; reasons for CPM may include diffuse microcalcifications, lobular carcinoma in situ, atypical hyperplasia, multicentric breast cancer, strong family history, the presence of a BRCA1 or BRCA2 mutation, dense breast tissue, or a large remaining breast (which complicates symmetric reconstructive techniques).
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Despite the availability of guidelines and genetic risk assessment, many patients choose bilateral mastectomy because of the fear of cancer occurring in the contralateral breast. Others choose bilateral mastectomy to avoid future surveillance or to achieve breast symmetry. Future research should focus on the development of decision aids for patients and surgeons.
